Last reviewed · How we verify
Curosurf
Curosurf, marketed by Jean Michel Hascoet, is a leading treatment for respiratory distress syndrome in newborns. The drug's key strength lies in its well-established market presence, supported by a key composition patent that remains in effect until 2028. The primary risk to Curosurf is the potential for increased competition as the patent approaches expiration.
At a glance
| Generic name | Curosurf |
|---|---|
| Also known as | poractant alfa, surfactant |
| Sponsor | Jean Michel Hascoet |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Respiratory distress syndrome in the newborn
Common side effects
- Bradycardia
- Hypotension
- Endotracheal tube blockage
- Oxygen desaturation
Serious adverse events
- Intracranial Hemorrhage
- Patent Ductus Arteriosus
- Pneumothorax
- Pulmonary Interstitial Emphysema
- Bronchopulmonary Dysplasia
- Acquired Septicemia
- Acquired Pneumonia
- Pulmonary hemorrhage
Key clinical trials
- The Budesonide in Babies (BiB) Trial (PHASE3)
- Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome (PHASE4)
- LISA in the Delivery Room for Extremely Preterm Infants (NA)
- Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants (NA)
- EXTERNAL NEGATIVE PRESSURE DURING LISA (NA)
- Duration of Surfactant Administration and Impact on Stabilisation of Vital Parameters in Very Preterm Neonates: 1 Minutes Versus 5 Minutes (PHASE4)
- Surfactant Therapy Via Supraglottic Airway to Preterm Neonates With RDS in Vietnam (NA)
- Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Curosurf CI brief — competitive landscape report
- Curosurf updates RSS · CI watch RSS
- Jean Michel Hascoet portfolio CI